Appendix C – Surveillance Form for Carbapenemase Producing Organisms (CPO)

Name of the Facility:		
1	Unique Identifier ¹ (assigned by BCPHMRL)	
2	Patient's status ☐ Inpatient ☐ Haemodialysis clinic patient ☐ Other, please specify	
3	Date of admission or visiting (dd/mmm/yyyy)	
4	CPO status ☐ Infection (please also complete appendix D) ☐ Colonization ☐ Unknown	
5a	(Optional) Was this patient treated with antimicrobials within TWO weeks prior to CPO detection? ☐ Yes ☐ No ☐ Unknown	
5b	(Optional) If Yes, which of these was / were used? (Check all that apply) □ Colistin □ Tigecycline □ Carbapenem □ Cephalosporin □ Chloramphenicol □ β-lactam inhibitor (eg. Pip/tazo) □ Aminoglycoside (amikacin, gentamicin, tobramycin) □ Other, please specify □	
6	Has the patient had an overnight stay in a hospital or undergone medical/surgical procedure outside of Canada within the past 12 months (or 6 months²)? Yes, please specify the name of the country No Unknown	
7	Has the patient had haemodialysis outside Canada within the past 12 months (or 6 months ²)? Yes, please specify the name of the country No Unknown	
8	Was the patient transferred from a unit with a high prevalence of CPO? ☐ Yes, please specify the name of the healthcare facility ☐ No ☐ Unknown	
9	Has the patient had close contact with a known CPO case within the past 12 months (or 6 months²)? Yes, please specify the nature of contact: Roommate in a healthcare facility Household Other, please specify Unknown	

^{1.} Contact BCPHMRL if the unique identifier has not been received

^{2.} Lack of consensus on the timeframe for the look back period. Communicate with PICNet if the reporting facility applies a different timeframe other than the past 12 months.

10	Is there any evidence that this case was associated with the reporting facility? ³
	☐ Yes ☐ No ☐ Unable to determine/No information available
11	Is there any evidence of transmission within the reporting facility? ⁴
	☐ Yes ☐ No ☐ Unable to determine/No information available
12	(Optional) Is there evidence that the patient has underlying medical condition(s)?
	☐ No evidence of any underlying medical condition
	☐ Yes (please check all that apply)
	☐ Diabetes
	☐ Liver disease
	☐ HIV infection
	☐ Cancer (active)
	☐ Lung disease (e.g., asthma, COPD)
	☐ Kidney disease (include all patients on dialysis)
	☐ Solid organ transplantation
	☐ Bone marrow transplantation
	☐ Other immune suppression, please specify
	☐ Heart disease (do NOT include hypertension alone, isolated atrial fib or mitral valve prolapse)
	☐ Other, please specify
	☐ Unknown/No information available

Once completed, please send it to:

Dr. Guanghong Han

Epidemiologist, Provincial Infection Control Network of BC 504 – 1001 West Broadway, Vancouver, BC V6H 4B1

Phone: (604) 875-4844 ext. 22983

Fax: (604) 875-4373

E-mail: Guanghong.Han@phsa.ca

^{3.} The CPO was identified more than 72 hours or 3 days after admission to the reporting facility and the patient did NOT have any of the following factors*:

a. an overnight stay in the hospital or medical/surgical procedure outside of Canada within the past 12 months

b. haemodialysis outside of Canada within the past 12 months

c. transferred from a healthcare unit or facility with a high prevalence of CPO

d. close contact with a known CPO case in their household or from another healthcare facility within the past 12 months

^{*} Lack of consensus regarding timeframe after admission. Communicate with PICNet if these criteria are not fully applied in the reporting facility.

^{4.} Same genotype of CPO and epidemiologic link to other CPO cases in the facility in terms of time and space, e.g., stay in the same unit, shared equipment or nursing staff

Appendix D – Addendum Form for Carbapenemase Producing Organisms (CPO) Infections

NB: This form should be complete if a) the case was identified as a CPO infection; b) the case was initially reported as colonization, and subsequently developed into a CPO infection within a year from initial identification. Please ensure that the CPO surveillance form (*Appendix C*) has been completed for this case.

Name of the Facility:		
1	Unique Identifier (assigned by BCPMHRL)	
2	Patients' status ☐ Inpatient ☐ Haemodialysis clinic patient ☐ Other, please specify	
3	Date of admission or visiting (dd/mmm/yyyy)	
4	Date of CPO infection identification (dd/mmm/yyyy)	
5	Site(s) of infection ☐ Bloodstream ☐ Urinary tract ☐ Respiratory tract ☐ Wound ☐ Surgical site ☐ Other, please specify	
6	Organism(s) isolated (Check all that apply) □ Acinetobacter spp. □ Serratia spp. □ Klebsiella pneumonia □ Enterobacter spp. □ Escherichia coli □ Proteus spp. □ Morganella morganii □ Citrobacter spp. □ Pseudomonas spp. □ Other Entero-bacteriaceae, please specify	
7	CPO gene(s) detected: NDM	
8a	Was the patient treated with an antibiotic for CPO infection? ☐ Yes ☐ No ☐ Unknown	
8b	(Optional) If Yes, which antibiotic(s) was / were used? (Check all that apply) □ Colistin □ Tigecycline □ Other, please specify	
9	Was ICU admission required due to CPO infections or the complications associated with CPO infection? ☐ Yes ☐ No ☐ N/A – patient was already in ICU ☐ Unknown	
10	Patient outcome 30 days or up until discharge after identification of CPO infection ☐ Patient alive, still in hospital 30 days after diagnosis ☐ Patient survived and discharged ☐ Patient survived and transferred ☐ Patient died	

Once completed, please send it to:

Dr. Guanghong Han

Epidemiologist, Provincial Infection Control Network of BC 504 – 1001 West Broadway, Vancouver, BC V6H 4B1

Phone: (604) 875-4844 ext. 22983

Fax: (604) 875-4373

E-mail: Guanghong.Han@phsa.ca